Publications by authors named "C Ridder"
Article Synopsis
- Conventional chemotherapy is limited by its non-selective nature, leading to severe side effects, but small-molecule drug conjugates (SMDCs) offer a more targeted delivery to tumors.
- The study introduces eSOMA-DM1, a new SMDC designed to target somatostatin receptor subtype 2 (SSTR2) and combines a cytotoxic agent with a chelate for improved monitoring and combination therapy.
- In experiments, eSOMA-DM1 showed promising tumor uptake in animal models, outperforming the traditional DOTA-TATE compound, while also demonstrating prolonged circulation in the bloodstream.
Background: Fibroblast activation protein (FAP), a transmembrane serine protease overexpressed by cancer-associated fibroblasts in the tumor stroma, is an interesting biomarker for targeted radionuclide theranostics. FAP-targeting radiotracers have demonstrated to be superior to [F]FDG PET/CT in various solid cancers. However, these radiotracers have suboptimal tumor retention for targeted radionuclide therapy (TRT).
View Article and Find Full Text PDFArticle Synopsis
- Photodynamic therapy (PDT) is a treatment using light that helps kill cancer cells, and it's more effective when a special dye called Bremachlorin is present in the tumor tissue.
- Scientists used special cameras to see how Bremachlorin spread in the body and found it worked best in the pancreatic tumors about 6 hours after it was given.
- They also used another dye called IRDye®-800CW to see how well PDT caused the tumors to break down, proving that this method is helpful in treating cancer.
eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors.
EJNMMI Radiopharm Chem
May 2024
Background: Integrating radioactive and optical imaging techniques can facilitate the prognosis and surgical guidance for cancer patients. Using a single dual-labeled tracer ensures consistency in both imaging modalities. However, developing such molecule is challenging due to the need to preserve the biochemical properties of the tracer while introducing bulky labeling moieties.
View Article and Find Full Text PDFThe addition of darolutamide, an androgen receptor signalling inhibitor, to therapy with docetaxel has recently been approved as a strategy to treat metastatic prostate cancer. OATP1B3 is an SLC transporter that is highly expressed in prostate cancer and is responsible for the accumulation of substrates, including docetaxel, into tumours. Given that darolutamide inhibits OATP1B3 in vitro, we sought to characterise the impact of darolutamide on docetaxel pharmacokinetics.
View Article and Find Full Text PDF